Royalty Pharma (RPRX) Divestments (2020 - 2026)

Royalty Pharma has reported Divestments for 7 years, with the latest figure at $42.3 million in Q1 2026.

• Quarterly Divestments rose 16.67% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.6 million (up 103.3% YoY) and the FY2025 annual result came in at $105.1 million, up 344.77% from the prior year.
• Divestments climbed to $42.3 million in Q1 2026 per RPRX's latest filing, from $5.0 million in the prior quarter.
• Over five years, Divestments peaked at $62.4 million in Q2 2025 and troughed at $905000.0 in Q3 2025.
• A 5-year average of $15.3 million and a median of $5.0 million in 2025 frame the typical range for Divestments.
• The widest YoY moves for Divestments: up 1500.0% in 2025, down 91.77% in 2025.
• Over 5 years, Divestments stood at $5.8 million in 2022, then decreased by 19.71% to $4.7 million in 2023, then plunged by 30.34% to $3.2 million in 2024, then jumped by 53.95% to $5.0 million in 2025, then soared by 747.14% to $42.3 million in 2026.
• According to Business Quant data, Divestments over the past three periods registered $42.3 million, $5.0 million, and $905000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.